Related Experiment Video

Updated: Jul 3, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

Quick identification of effective small interfering RNAs that inhibit the replication of coxsackievirus A16

Zhiqiang Wu1, Yongzhen Gao, Lilian Sun

  • 1State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China.

Antiviral Research
|July 30, 2008
PubMed

Insights

RNA interference (RNAi) offers a promising new therapy for Coxsackievirus A16 (CA16), the virus causing hand, foot, and mouth disease (HFMD). This study designed small interfering RNAs (siRNAs) to effectively inhibit CA16 replication in cell cultures.

Area of Science:

  • Virology
  • Molecular Biology
  • Therapeutics

Background:

  • Coxsackievirus A16 (CA16) is a primary cause of hand, foot, and mouth disease (HFMD), with severe complications like myocarditis and fatal shock.
  • Current therapeutic options for CA16 infections are limited, necessitating the development of novel treatment strategies.

Purpose of the Study:

  • To investigate the potential of RNA interference (RNAi) as a therapeutic approach against CA16.
  • To design and evaluate small interfering RNAs (siRNAs) targeting conserved regions of the CA16 genome for antiviral activity.

Main Methods:

  • Sequencing and comparative analysis of the CA16 Shzh05-1 strain against other CA16 strains.
  • Design and synthesis of 30 siRNAs targeting conserved viral regions and construction of siRNA-encoding plasmids.
  • In vitro assessment of siRNA efficacy in blocking CA16 replication in cultured cells.

Main Results:

  • Thirteen designed siRNAs demonstrated significant inhibition of CA16 replication in cell cultures.
  • Combined transfection of effective siRNAs resulted in a high level of viral replication suppression.
  • Identification of conserved regions crucial for siRNA targeting in CA16.

Conclusions:

  • RNAi, utilizing specifically designed siRNAs, shows significant potential as a therapeutic strategy for managing CA16 infections.
  • The developed siRNAs effectively suppress CA16 replication, offering a novel avenue for antiviral treatment.
  • Targeting conserved genomic regions provides a robust approach for developing broad-spectrum antiviral RNAi therapies.

More Related Videos

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors06:02

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...